Skip to main content

Get 25% off your first bioreagent online order — use code: PROTEOSHOP25

Brand: ProteoGenix

Recombinant Human G0S2 Protein, N-His-SUMO & C-Strep

Host species:
Escherichia coli (E.coli)
Origin species:
Human
Molecular weight:
24.81 kDa

$392.00

100ug + 392 loyalty points
Glu2–Ser103
  • In Stock
  • Wide range of unique reagents
  • Fast worldwide delivery
Recombinant Human G0S2 Protein, N-His-SUMO & C-Strep

Recombinant Human G0S2 Protein, N-His-SUMO & C-Strep

Product name Recombinant Human G0S2 Protein, N-His-SUMO & C-Strep
Origin species Human
Expression system Prokaryotic expression
Molecular weight 24.81 kDa
Buffer Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Delivery condition Dry Ice
Delivery lead time in business days 3-5 days if in stock; 3-5 weeks if production needed
Storage condition 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
Brand ProteoGenix
Host species Escherichia coli (E.coli)
Fragment Type Glu2-Ser103
Aliases /Synonyms G0/G1 switch protein 2, G0/G1 switch regulatory protein 2, G0S2, Putative lymphocyte G0/G1 switch gene
Reference ARO-P12290
Note For research use only.
Molecular Constructor
Glu2–Ser103

Recombinant Human G0S2 Protein: Structure, Activity, and Applications

The Recombinant Human G0S2 Protein, also known as G0S2, is a protein that plays a crucial role in regulating cellular metabolism and energy balance. It is a member of the G0/G1 switch gene family and is highly expressed in adipose tissue, liver, and skeletal muscle. The G0S2 gene has been identified as a potential target for treating metabolic disorders such as obesity and type 2 diabetes.

Structure of Recombinant Human G0S2 Protein

The G0S2 protein is composed of 103 amino acids and has a molecular weight of approximately 11.7 kDa. It contains a conserved N-terminal domain and a C-terminal domain that are connected by a flexible linker region. The N-terminal domain is responsible for binding to other proteins, while the C-terminal domain is involved in regulating the activity of G0S2.

The crystal structure of G0S2 has been determined, revealing a compact globular protein with a four-helix bundle fold. The N-terminal domain forms two α-helices, while the C-terminal domain consists of two shorter α-helices and a β-strand. This unique structure allows G0S2 to interact with multiple proteins and regulate their function.

Activity of Recombinant Human G0S2 Protein

G0S2 has been identified as a potent inhibitor of adipose triglyceride lipase (ATGL), an enzyme responsible for breaking down stored fat into free fatty acids. By binding to ATGL, G0S2 prevents its activity and inhibits the breakdown of fat, thereby reducing the availability of fatty acids for energy production. This results in an increase in the storage of fat in adipose tissue, contributing to the development of obesity.

In addition to its role in regulating fat metabolism, G0S2 has also been implicated in the regulation of glucose metabolism. It has been shown to interact with and inhibit the activity of the enzyme pyruvate dehydrogenase kinase 4 (PDK4), which is involved in the conversion of pyruvate to glucose. This inhibition leads to a decrease in glucose production, which may be beneficial for individuals with type 2 diabetes.

Applications of Recombinant Human G0S2 Protein

The unique structure and activity of G0S2 make it a promising target for therapeutic interventions in metabolic disorders. Recombinant Human G0S2 Protein can be produced in large quantities using recombinant DNA technology, making it readily available for research and potential clinical use.

One potential application of G0S2 is in the treatment of obesity. By inhibiting ATGL, G0S2 can reduce the breakdown of fat and promote fat storage, which may be beneficial for individuals with obesity. In animal studies, administration of G0S2 has been shown to decrease body weight and fat mass, as well as improve insulin sensitivity and glucose tolerance.

Another potential application of G0S2 is in the treatment of type 2 diabetes. By inhibiting PDK4, G0S2 can reduce glucose production and improve glucose control. In animal models, G0S2 has been shown to improve glucose tolerance and insulin sensitivity, suggesting its potential as a therapeutic target for type 2 diabetes.

In addition, G0S2 has also been studied for its role in cancer. It has been found to be downregulated in certain types of cancer, and its overexpression has been shown to inhibit cancer cell growth and promote cell death. Further research is needed to fully understand the role of G0S2 in cancer and its potential as a therapeutic target.

Conclusion

The Recombinant Human G0S2 Protein is a unique protein with a crucial role in regulating metabolism and energy balance. Its structure and activity make it a promising target for therapeutic interventions in

There are no reviews yet.

Be the first to review “Recombinant Human G0S2 Protein, N-His-SUMO & C-Strep”

Your email address will not be published. Required fields are marked *

Recently viewed products

Loading recently viewed products…

Can’t find what you need?

Our catalog doesn’t cover everything — but our team does. Whether you need a custom antibody, a specific protein variant, or a bulk order, our scientists are here to help.

Contact Our Team Book a Call

Cart (0 Items)

Your cart is currently empty.

View Products